Stock Price Prediction

VistaGen Therapeutics (VTGN) has a bullish outlook with a price target of $12.00, supported by strong clinical progress in Phase 3 trials for social anxiety disorder and plans for further studies in major depressive disorder. The company’s robust financial position, with $97.6 million in cash reserves, ensures operational stability through fiscal year 2026, bolstering investor confidence. Additionally, a recent Zacks Rank #2 (Buy) upgrade highlights positive earnings estimate revisions, suggesting potential near-term stock price appreciation.

VTGN stock is bearish due to its weak financial performance and market underperformance. The stock closed at $2.89 on January 31, 2025, down 39.7% year-to-date, with quarterly losses exceeding estimates and revenue missing by 45.37%. Additionally, its Zacks Rank #3 (Hold) suggests limited upside potential in the near term.

The market consensus for VTGN's revenue in the upcoming quarter is projected to be approximately $179.25K USD.